Evidence map›Paper›PMID 41484337›Full record

ArticleScientific reports2026

Association between platelet-to-lymphocyte ratio and high risk for prostate cancer among middle-aged and older US men.

Yifan Chang, Weibo Wang, Junyue Tao, Zhenbin Zheng, Jun Zhou

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yifan Chang *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Weibo Wang *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Junyue TaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Zhenbin ZhengDepartment of Hemodialysis, Yushan Bo'ai Hospital, Yushan, Jiangxi, People's Republic of China. zhenb_zheng@126.com.
Jun ZhouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. urodoctorzhoujun@163.com.

Funding

the Health Committee of Anhui Province, China No. AHWJ2023BAc10007the Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities No. 2022AH010071
6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the most common malignancies among men worldwide, and growing evidence implicates inflammation as a key contributor to its initiation and progression. Among various inflammatory markers, the platelet-to-lymphocyte ratio (PLR) has gained attention due to its simplicity, non-invasiveness, and clinical relevance. This study aims to evaluate the association between PLR levels and PCa risk in middle-aged and older U.S. men using nationally representative data. This study conducted a cross-sectional evaluation using data derived from the National Health and Nutrition Examination Survey (NHANES) spanning 2001 to 2010, aiming to investigate a possible link between the PLR and PCa risk. The PLR was determined by dividing the platelet count by the lymphocyte count. Individuals were classified as high risk for PCa if total PSA (tPSA) exceeded 10 ng/mL, or ranged from 4 to 10 ng/mL with a free-to-total PSA (f/t PSA) ratio ≤ 25%. Others were categorized as low risk. To evaluate the association between PLR and PCa risk, multivariate logistic regression and restricted cubic spline models were employed. Stratified subgroup analyses were conducted to explore potential effect modification across different populations, while supplementary sensitivity analyses were performed to confirm the stability and reliability of the results. Among the 6,285 participants, 437 (4.86%) were classified as the high risk for PCa. After controlling for potential confounding variables, each 10-unit increase in PLR corresponded to a 3% elevation in high risk for PCa (OR 1.03, 95% CI 1.02-1.05). Individuals in the top quartile of PLR had a 74% greater high risk of PCa than those in the bottom quartile (OR 1.74, 95% CI 1.24-2.45). A restricted cubic spline model demonstrated a significant linear relationship between PLR and high risk for PCa. Additional sensitivity analyses reinforced the stability of these observed associations. Stratified analyses demonstrated that the link between PLR and PCa risk persisted consistently across diverse demographic and clinical categories, such as age, marital status, body mass index, smoking behavior, alcohol consumption, hypertension, and diabetes status. Within the U.S. middle-aged and elderly population, PLR exhibits a significant linear association with high risk for PCa. These findings suggest that PLR may serve as an epidemiological reference indicator for identifying individuals with potentially elevated PCa risk.

Indexed as

Blood PlateletsLymphocytesProstatic NeoplasmsAgedCross-Sectional StudiesHumansLymphocyte CountMaleMiddle AgedNutrition SurveysPlatelet CountProstate-Specific AntigenRisk FactorsUnited StatesProstate-Specific AntigenInflammationInflammatory markersMiddle-aged and older adultsNHANESPlatelet-to-lymphocyte ratioProstate cancerProstate-specific antigenUnited states

Identifiers

PMID41484337
PMCPMC12858942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.